Skip to main content

Table 1 Baseline characteristics of 140 HIV-infected patients

From: Durability of Stavudine, Lamivudine and Nevirapine among Advanced HIV-1 Infected Patients with/without Prior Co-administration of Rifampicin: A 144-week Prospective Study

Characteristics Total (n = 140) TB Group (n = 70) Control Group (n = 70) Pvalue
Gender: Male 95 (68%) 56 (80%) 39 (56%) 0.002
Age, years, mean ± SD 35.7 ± 7.6 34.4 ± 6.2 37.2 ± 8.7 0.028
Body weight, Kgs, mean ± SD 54.6 ± 9.6 54.7 ± 8.7 54.4 ± 10.6 0.827
Body mass index, mean ± SD 20.1 ± 2.9 19.7 ± 2.4 20.5 ± 3.4 0.097
CD4 cell counts, cells/mm3, mean ± SD 62 ± 74 61 ± 74 76 ± 75 0.823
%CD4, median (IQR) 5 ± 5 6 ± 5 5 ± 5 0.226
Plasma HIV RNA, copies/ml, median (IQR) 433,500 (169,000–750,000) 505,000 (269,000–750,000) 291,000 (94,600–714,000) 0.014
Plasma HIV RNA, Log copies/ml, median (IQR) 5.6 (5.2–5.9) 5.7 (5.4–5.9) 5.6 (5.0–5.9) 0.004
ALP, mg/dl, median (IQR) 98 (71–142) 110 (75–154) 91 (70–128) 0.072
AST, U/l, median (IQR) 30 (20–50) 36 (27–60) 35 (26–47) 0.371
ALT, U/l, median (IQR) 27 (19–42) 27 (18–51) 32 (22–49) 0.169
Total bilirubin, mg/dl, median (IQR) 0.6 (0.4–0.7) 0.6 (0.5–0.8) 0.5 (0.4–0.7) 0.051
  1. IQR = interquartile range